Table 1.
Clinical data at baseline of 3 groups with HBsAg seroclearance as determined by the Abbott Architect assay
| Patient characteristic | Data for group (n): |
||
|---|---|---|---|
| Spontaneous HBsAg loss (10) | NA treated (8)a | Acute hepatitis (8) | |
| Age at first visit or medication (yr) | 60.6 ± 12.6 | 46.8 ± 12.2 | 50.5 ± 10.8 |
| Sex (no. of males/no. of females) | 10/0 | 7/1 | 8/0 |
| Route of infection (no. of vertical/no. of horizontal) | 10/0 | 4/4 | 0/8 |
| No. with genotype Aa/Ae/Ba/Bj/C | 0/0/0/2/8 | 1/1/1/1/4 | 1/4/1/0/2 |
| Clinical data | |||
| ALT (median [range]) (IU/liter) | 23.5 (8–51) | 76 (11–220) | 1,682 (455–3,622) |
| HBeAg (no. positive/no. negative) | 0/10 | 5/3 | 8/0 |
| HBV DNA (median [range]) (log copies/ml) | 2.3 (<2.1 to 3.4) | 7.4 (4.1 to >9.1) | 6.5 (3.8–8.5) |
| HBcrAg (median [range]) (log IU/ml) | <3 (<3 to 3.3) | 6.8 (4.2–8.6) | 7.1 (6.6–8) |
| Abbott Architect HBsAg-QT detection (median [range]) (mIU/ml) | 1,300 (<50 to 10,880) | 2,676,800 (9,680–89,679,600) | 362,500 (91,200–40,000,000) |
| NA therapy (no. with none/no. with LVD/no. with ETV)b | 10/0/0 | 0/2/6 | 5/0/3 |
a
NA, nucleotide analogue.
b
LVD, lamivudine; ETV, entecavir.